Conatus Pharmaceuticals Inc. | Uncategorized | Business Contracts

Engagement Letter, dated March 1, 2022, between the Company and H.C. Wainwright & Co., LLC (Filed With SEC on March 25, 2022)

Description of Securities (Filed With SEC on March 10, 2022)

Executive Agreement, dated November 5, 2021, by and between the Company and Steven J. Mento, Ph.D (Filed With SEC on November 8, 2021)

Amendment to Engagement Letter between Histogen Inc. and H.C. Wainwright & Co., LLC, dated as of June 6, 2021 (Filed With SEC on June 8, 2021)

Engagement Letter between Histogen Inc. and H.C. Wainwright & Co., LLC, dated as of December 28, 2020 (Filed With SEC on December 29, 2020)

Engagement Letter between Histogen Inc. and H.C. Wainwright & Co., LLC, dated as of November 10, 2020 (Filed With SEC on November 12, 2020)

Second Amended and Restated Strategic Relationship Success Fee Agreement, dated January 28, 2020, by and between Histogen Inc. and Lordship Ventures LLC (Filed With SEC on February 7, 2020)

Letter Agreement, dated November 8, 2019, by and between Histogen Inc. and Canaccord Genuity LLC (Filed With SEC on February 7, 2020)

Support Agreement, dated January 28, 2020 by and among Conatus Pharmaceuticals Inc., Histogen Inc. and certain stockholders of Conatus Pharmaceuticals Inc (Filed With SEC on January 28, 2020)

Support Agreement, dated January 28, 2020, by and among Conatus Pharmaceuticals Inc., Histogen Inc. and certain stockholders of Histogen Inc (Filed With SEC on January 28, 2020)

Conatus Pharmaceuticals Inc. (84) | Uncategorized (10)